Format

Send to

Choose Destination
Sci Transl Med. 2018 Jan 31;10(426). pii: eaan5174. doi: 10.1126/scitranslmed.aan5174.

Tissue-resident mesenchymal stromal cells: Implications for tissue-specific antifibrotic therapies.

Author information

1
Renal Division, Brigham and Women's Hospital, Boston, MA 02115, USA. dlemos@bwh.harvard.edu jeremysd@u.washington.edu.
2
Harvard Medical School, Boston, MA 02115, USA.
3
Department of Medicine, University of Washington, Seattle, WA 98195, USA. dlemos@bwh.harvard.edu jeremysd@u.washington.edu.
4
Research and Development, Vertex Pharmaceuticals, Boston, MA 02210, USA.

Abstract

Recent scientific findings support the notion that fibrosis is driven by tissue-specific cellular and molecular mechanisms. Analysis of seemingly equivalent mesenchymal stromal cell (MSC) populations residing in different organs revealed unique properties and lineage capabilities that vary from one anatomical location to another. We review recently characterized tissue-resident MSC populations with a prominent role in fibrosis and highlight therapeutically relevant molecular pathways regulating their activity in chronic disease.

PMID:
29386358
DOI:
10.1126/scitranslmed.aan5174
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center